An Open-label, Parallel-group, Randomized Study to Evaluate the Absolute Bioavailability of Single Dose Subcutaneous Administration of Lecanemab in Healthy Subjects
Latest Information Update: 28 Aug 2023
At a glance
- Drugs Lecanemab (Primary) ; Lecanemab (Primary)
- Indications Alzheimer's disease
- Focus Pharmacokinetics
- Sponsors Eisai Inc
- 20 Jul 2023 Results of pooled analysis from NCT05045716 and NCT05533801 comparable efficacy and improved safety compared to lecanemab IV in early Alzheimers disease (AD presented at the Alzheimer's Association International Conference 2023
- 04 Aug 2022 Results presented at the Alzheimer's Association International Conference 2022
- 03 Aug 2022 Results presented in an Eisai Co Ltd Media Release.